| Company/Division name | Fujifilm Diosynth Biotechnologies |
| Parent company | FUJIFILM Holdings Corporation |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 725 |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 2000 |
| Country(ies) from which reshored: | Japan |
| City reshored to: | Holly Springs |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | biopharmaceutical medicines, cell cultures |
| What non-domestic negative factors made offshoring less attractive? | Green considerations |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, Infrastructure, Impact on domestic economy |
| Government Incentive dollar amount: | $21.7 million |
